Literature DB >> 29123775

Early initiation of steroid pulse therapy for neuromyelitis optica in an emergency room setting.

Saya Yamada1, Sayaka Oikawa1, Teppei Komatsu2, Toshiaki Hirai2, Kenji Dohi1, Takeki Ogawa1.   

Abstract

Case: A 40-year-old man presented to the emergency room with visual impairment, dysesthesia of lower legs, and urinary retention. Two days before admission, he was consulted to the neurology department due to bilateral optic neuritis and scheduled the magnetic resonance imaging of spine. However, the urinary retention deteriorated acutely and he came to the emergency room. On arrival, the plain magnetic resonance image of his spine showed diffuse hyperintensity signals of the spinal cord in T2-weighted images. He was diagnosed with neuromyelitis optica and steroid pulse therapy was initiated. Outcome: We began treatment immediately in the emergency room, cooperating with the neurology team. After admission, plasmapheresis was added for his fluctuating symptoms. On hospital day 7, he was discharged without complication.
Conclusion: It is important to understand the various clinical manifestations of neuromyelitis optica. In emergency settings, immediate steroid therapy is necessary for better outcomes.

Entities:  

Keywords:  Emergency room; myelitis; optic neuritis; steroid; treatment

Year:  2015        PMID: 29123775      PMCID: PMC5667370          DOI: 10.1002/ams2.155

Source DB:  PubMed          Journal:  Acute Med Surg        ISSN: 2052-8817


  9 in total

1.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

Review 2.  EFNS guidelines on diagnosis and management of neuromyelitis optica.

Authors:  J Sellner; M Boggild; M Clanet; R Q Hintzen; Z Illes; X Montalban; R A Du Pasquier; C H Polman; P S Sorensen; B Hemmer
Journal:  Eur J Neurol       Date:  2010-06-07       Impact factor: 6.089

Review 3.  Devic's neuromyelitis optica: clinical features and prognostic factors.

Authors:  R Bergamaschi; A Ghezzi
Journal:  Neurol Sci       Date:  2004-11       Impact factor: 3.307

4.  Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.

Authors:  Douglas Kazutoshi Sato; Dagoberto Callegaro; Marco Aurelio Lana-Peixoto; Patrick J Waters; Frederico M de Haidar Jorge; Toshiyuki Takahashi; Ichiro Nakashima; Samira Luisa Apostolos-Pereira; Natalia Talim; Renata Faria Simm; Angelina Maria Martins Lino; Tatsuro Misu; Maria Isabel Leite; Masashi Aoki; Kazuo Fujihara
Journal:  Neurology       Date:  2014-01-10       Impact factor: 9.910

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica.

Authors:  S Watanabe; I Nakashima; T Misu; I Miyazawa; Y Shiga; K Fujihara; Y Itoyama
Journal:  Mult Scler       Date:  2007-01       Impact factor: 6.312

7.  Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.

Authors:  Angelo Ghezzi; Roberto Bergamaschi; Vittorio Martinelli; Maria Trojano; M Rosaria Tola; Elisa Merelli; Luigi Mancardi; Paolo Gallo; Massimo Filippi; Mauro Zaffaroni; Giancarlo Comi
Journal:  J Neurol       Date:  2004-01       Impact factor: 4.849

Review 8.  Neuromyelitis optica: concept, immunology and treatment.

Authors:  Akiyuki Uzawa; Masahiro Mori; Satoshi Kuwabara
Journal:  J Clin Neurosci       Date:  2013-08-02       Impact factor: 1.961

Review 9.  Immunotherapy of neuromyelitis optica.

Authors:  Benjamin Bienia; Roumen Balabanov
Journal:  Autoimmune Dis       Date:  2013-12-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.